益生菌类制剂治疗非酒精性脂肪性肝病疗效评价

发布时间：2018-05-20 09:30

  本文选题：益生菌 + 非酒精性脂肪肝　； 参考：《山东医药》2015年07期

【摘要】：目的系统评价益生菌制剂对非酒精性脂肪性肝病(NAFLD)的疗效。方法检索2014年5月之前在Pub Med、Springer Link、CNKI中文期刊全文数据库、维普中文科技期刊数据库网及万方数据库中发表的文献,选取关于益生菌制剂治疗NAFLD的随机对照试验,由2名研究者独立对文献进行质量评价和数据提取,应用Rev Man5.1软件进行Meta分析。连续性变量计量单位相同采用加权均数差(WMD)进行评估。结果共纳入8项符合标准的随机对照试验相关文献,NAFLD患者共543。Meta分析显示:与对照组相比,益生菌制剂能明显降低NAFLD患者的ALT(WMD=17.74,95%CI:12.23~23.14,P0.000 01)、AST(WMD=9.01,95%CI:8.13~9.89,P0.000 01)、GGT(WMD=16.48,95%CI:1.91~31.05,P=0.03)、CHO(WMD=0.24,95%CI:0.16~0.31,P0.000 01)和TG(WMD=0.29,95%CI:0.13~0.45,P=0.000 4)水平,不能改善BMI(WMD=0.04,95%CI:-0.48~0.57,P=0.87)。结论益生菌制剂可降低NAFLD患者ALT、AST、GGT、CHO和TG水平,促进肝功能的恢复,但对患者的BMI无改善作用。
[Abstract]:Objective to evaluate the efficacy of probiotics in the treatment of nonalcoholic fatty liver disease (NAF LDD). Methods to search the literature published in the Chinese journal full-text database of Pub Medtrol Springer Linkr Linki before May 2014, the database network of Chinese scientific and technological journals of Weipu and Wanfang database, and to select a randomized controlled trial of probiotics in treating NAFLD. The quality evaluation and data extraction of the literature were carried out by two researchers independently, and Meta analysis was carried out by using Rev Man5.1 software. The same unit of measurement of continuous variables was evaluated using weighted mean difference (WMD). 缁撴灉鍏辩撼鍏，

本文编号：1914083